Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Novitium Pharma LLC
EIR
•Novitium Pharma LLC•February 4, 2019

Novitium Pharma LLC – FDA EIR, Feb 4, 2019

Record Details

An FDA inspection of Novitium Pharma LLC, located in East Windsor, NJ, was conducted from January 23 to February 4, 2019. This was the company's initial general Current Good Manufacturing Practice (cGMP) inspection, following established FDA guidelines for drug manufacturing. The inspection covered critical operational systems including Quality, Laboratory, Facilities, Production, Packaging and Labeling, and Material Systems. The inspection identified several deficiencies, resulting in an FDA-483 form with observations. Key issues included inadequate assessment and control of changes to approved drug applications by the quality unit, incomplete laboratory records for testing and standardization of reference standards, and a lack of written and fully followed procedures for the quality control unit. Further verbal observations highlighted the absence of control procedures to validate manufacturing processes, deficient procedures for managing drug product quality risks, inadequate control over electronic records (specifically unreviewed audit trails and reporting functions), and unjustified deviations from written test procedures. In response to the findings, Novitium Pharma LLC's management acknowledged the observations at the closeout meeting and committed to implementing necessary corrections, providing a written response within 15 days. Additional records were also supplied to the inspectors during the closeout discussions.

Company
Novitium Pharma LLC
Inspection date
February 4, 2019
Product type
drugs
Office
New Jersey District Office
Person
  • Frederick Razzaghi (Advisor)
View Company Profile

ID · 8bb3a6b0-918c-4b76-a815-c77422ac59c5

Violation Codes7
21 CFR 820.19821 CFR 21121 CFR 314.8021 CFR 1121 CFR 820.5021 CFR 314.70FD&C Act 704(a)

Full citation text and observation details available on the Dashboard.

Other documents for Novitium Pharma LLC
  • 483 - 2026-07-22July 22, 2026
  • 483 - 2021-07-08July 8, 2021
  • 483 - 2019-02-04February 4, 2019
  • EIR - 2018-09-11September 11, 2018
  • EIR - 2018-05-09May 9, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novitium Pharma LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.